Skip to main content
MedPathMedPath Home
Clinical Trials/NCT02145689
NCT02145689
Withdrawn
Phase 3

Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity

Allergan0 sitesAugust 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMuscle SpasticityStroke

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Muscle Spasticity
Sponsor
Allergan
Primary Endpoint
Change from Baseline in the Modified Ashworth Scale-Bohannon (MAS-B) Score of Treated Muscle Groups Using a 6-Point Scale
Status
Withdrawn
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

This is a long-term safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity.

Registry
clinicaltrials.gov
Start Date
August 2014
End Date
May 2017
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Allergan
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •For patients entering from the 191622-127 study, successful completion of study 191622-127
  • •For patients entering directly into study 191622-129, upper limb spasticity in the elbow and shoulder due to stroke, with the most recent stroke at least 3 months ago

Exclusion Criteria

  • •Spasticity in the non-study upper limb that requires treatment
  • •Presence of fixed contractures in of the study muscles in elbow or shoulder
  • •Profound atrophy of muscles to be injected
  • •Previous surgical intervention, nerve block, or muscle block for the treatment of spasticity in the study limb in the last 12 months
  • •Injection of corticosteroids or anesthetics, use of casting or dynamic splinting or constraint-induced movement therapy (CIMT) for the study limb within 3 months
  • •Ultrasound therapy, electrical stimulation, or acupuncture in the study limb within 1 month
  • •Condition other than stroke contributing to upper limb spasticity
  • •Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, and/or amyotrophic lateral sclerosis

Outcomes

Primary Outcomes

Change from Baseline in the Modified Ashworth Scale-Bohannon (MAS-B) Score of Treated Muscle Groups Using a 6-Point Scale

Time Frame: Baseline, Up to 60 Weeks

Secondary Outcomes

  • Change from Baseline in the 19-Item Spasticity Impact Assessment-Upper Limb (SIA-UL) Score(Baseline, Up to 60 Weeks)
  • Clinical Global Impression (CGI) of Overall Change by Physician Compared to Baseline Using a 9-Point Scale(Baseline, Up to 60 Weeks)
  • Change from Baseline in Pain on an 11-Point Scale(Baseline, Up to 60 Weeks)

Similar Trials

Terminated
Phase 3
OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb SpasticityMuscle SpasticityStroke
NCT02145676Allergan53
Completed
Phase 3
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor OveractivityUrinary Incontinence
NCT01852058Allergan95
Completed
Not Applicable
Toxin Retrospective StudyNeurogenic Bladder
NCT03042052Centre d'Investigation Clinique et Technologique 805292
Completed
Phase 4
Sustained onabotulinumtoxinA Therapeutic Benefits in Patients With Chronic MigraineMigraine Disorders
NCT03606356Corfu Headache Clinic56
Completed
Not Applicable
An Observational Study of BOTOX® as Headache Prophylaxis for Chronic MigraineMigraine Disorders
NCT01686581Allergan641